Developing covid-19 vaccines at pandemic speed

Nicole Lurie, Melanie Saville, Richard Hatchett, Jane Halton

Research output: Contribution to journalReview articlepeer-review

1073 Citations (Scopus)

Abstract

The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine development. Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to epidemics of H1N1 influenza, Ebola, Zika, and now SARS-CoV-2. An H1N1 influenza vaccine was developed relatively rapidly, largely because influenza-vaccine technology was well developed and key regulators had previously decided that vaccines made using egg- and cell-based platforms could be licensed under the rules used for a strain change. Although a monovalent H1N1 vaccine was not available before the pandemic peaked in the Northern Hemisphere, it was available soon afterward as a stand-alone vaccine and was ultimately incorporated into commercially available seasonal influenza vaccines.
Original languageEnglish
Pages (from-to)1969-1973
Number of pages5
JournalNew England Journal of Medicine
Volume382
Issue number21
DOIs
Publication statusPublished - 21 May 2020

Fingerprint

Dive into the research topics of 'Developing covid-19 vaccines at pandemic speed'. Together they form a unique fingerprint.

Cite this